An Open Label Study of the Efficacy, Safety, and Pharmacoeconomics of Oral Ibandronate (Bondronat 50 mg) in Treatment of Metastatic Bone Disease
Phase of Trial: Phase IV
Latest Information Update: 28 Sep 2015
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Breast cancer; Cancer metastases
- Focus Therapeutic Use
- Sponsors Roche
- 28 Sep 2015 New Source identified and integrated ( ClinicalTrials.gov:NCT02564107)
- 23 Feb 2010 Actual initiation date (Nov 2004) added as reported by Roche record.
- 17 Jul 2008 New trial record.